Verastem, Inc. (operating commercially as Verastem Oncology) is a publicly traded, commercial-stage biopharmaceutical enterprise focused on discovering, developing, and delivering breakthrough targeted cancer therapies designed to improve survival outcomes for patients battling hard-to-treat solid tumors.